We aim to seek out autoimmunity early to intercept and prevent debilitating and life-threatening diseases. We have purposefully created a pipeline of investigational candidates that target upstream autoimmune pathways, even viral triggers, with the goal of intercepting and preventing life-threatening and debilitating immune-mediated diseases, including type 1 diabetes (T1D), celiac disease and lupus.
Our most advanced investigational candidate is PRV-031 (teplizumab), an anti-CD3 monoclonal antibody that is being developed for the delay of T1D in at-risk individuals, as indicated by the presence of two or more T1D-related to antibodies and evidence of dysglycemia.